ZIOP Share Price | Alaunos Therapeutics, Inc. Stock Analysis & Recommendation

Q: How big is Alaunos Therapeutics, Inc.?

Market Cap: As of Jun 18, Alaunos Therapeutics, Inc. has a market capitalization of 6.00 million, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, Alaunos Therapeutics, Inc. reported net sales of 0.00 million and a net profit of -4.07 million.Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 2.06 million and total assets of 2.75 million.

Q: What does Alaunos Therapeutics, Inc. do?

Overview:Alaunos Therapeutics, Inc. is a biopharmaceutical company focused on developing cancer therapies in the immuno-oncology sector, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.Financial Snapshot:Most recent Net Sales: 0 Million (Quarterly Results - Mar 2025) Most recent Net Profit: -1 Million (Quarterly Results - Mar 2025) Market cap: USD 6.00 Million (Micro Cap)Key Metrics:P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -0.30 Return on Equity: -384.78% Price to Book: 5.67Contact Details:Address: One First Avenue Parris Building 34 Navy Yard Plaza BOSTON MA : 02129 Tel: ['1 617 2591970', '1 617 5021881'] Fax: 1 617 2412855 Website: http://www.ziopharm.com/

Q: Is Alaunos Therapeutics, Inc. overvalued or undervalued?

As of 14 November 2023, Alaunos Therapeutics, Inc. has moved from a valuation grade of risky to does not qualify. The company is currently considered overvalued, given its significant negative financial ratios, including a Price to Book Value of 4.70 and an EV to EBITDA of -1.12. The return on capital employed (ROCE) is alarmingly low at -416.30%, indicating severe operational inefficiencies.In comparison to its peers, Alaunos Therapeutics has a worse EV to EBITDA ratio than MAIA Biotechnology, Inc. at -2.1328 and MiNK Therapeutics, Inc. at -3.4718, both of which also do not qualify for a positive valuation. Despite a recent surge in stock price with a 1-month return of 68.42%, the overall financial health and valuation metrics suggest that the company remains overvalued in the current market landscape.

Q: Is Alaunos Therapeutics, Inc. technically bullish or bearish?

As of 8 September 2025, the technical trend for Alaunos Therapeutics, Inc. has changed from sideways to mildly bullish. The daily moving averages indicate a mildly bullish stance, while the monthly MACD is also mildly bullish. However, the weekly MACD and KST are bearish, and the Bollinger Bands show a mildly bearish trend in both weekly and monthly perspectives. The Dow Theory indicates a mildly bullish trend on the weekly timeframe. In terms of performance, the stock has outperformed the S&P 500 over the past week and month, with returns of 3.36% and 5.58%, respectively, compared to the S&P 500's 1.05% and 2.33%. However, over the longer term, the stock has significantly underperformed the benchmark, with a 1-year return of -21.15% versus the S&P 500's 17.14%. Overall, the current technical stance is mildly bullish, but caution is warranted due to mixed signals from various indicators.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

210

Shareholding (Dec 2025)

FII

0.08%

Held by 6 FIIs

DII

97.51%

Held by 2 DIIs

Promoter

0.00%

How big is Alaunos Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Alaunos Therapeutics, Inc. has a market capitalization of 6.00 million, with net sales of 0.00 million and a net profit of -4.07 million over the latest four quarters. The company reported shareholder's funds of 2.06 million and total assets of 2.75 million as of Dec 24.

View full answer

What does Alaunos Therapeutics, Inc. do?

22-Jun-2025

Alaunos Therapeutics, Inc. is a micro-cap biopharmaceutical company focused on developing cancer therapies in the immuno-oncology sector. As of March 2025, it reported net sales of $0 million and a net loss of $1 million, with a market cap of $6 million.

View full answer

Who are in the management team of Alaunos Therapeutics, Inc.?

22-Jun-2025

As of March 2022, the management team of Alaunos Therapeutics, Inc. includes Chairman James Huang, CEO Dr. Laurence Cooper, Lead Independent Director Heidi Hagen, and Directors J. Kevin Buchi, Jaime Vieser, Holger Weis, and Independent Director Dr. Christopher Bowden. They oversee the company's strategic direction and operations.

View full answer

Is Alaunos Therapeutics, Inc. overvalued or undervalued?

25-Jun-2025

As of November 14, 2023, Alaunos Therapeutics, Inc. is considered overvalued with a valuation grade of "does not qualify" due to significant negative financial ratios, including a Price to Book Value of 4.70 and a ROCE of -416.30%, despite a recent stock price surge.

View full answer

Is Alaunos Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of September 8, 2025, Alaunos Therapeutics, Inc. shows a mildly bullish trend based on daily moving averages and monthly MACD, but mixed signals from weekly indicators and significant long-term underperformance compared to the S&P 500 suggest caution.

View full answer

Compare Alaunos Therapeutics, Inc. with Similar Stocks

Co-Diagnostics, Inc.IN8bio, Inc.Leap Therapeutics, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 7 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.69

Return on Equity

-142.49%

Price to Book

2.60

Revenue and Profits:

Net Sales:

0 Million

(Quarterly Results - Dec 2025)

Net Profit:

-1 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

0.0%

6 Months

6.91%

1 Year

-8.36%

2 Years

-79.77%

3 Years

348.96%

4 Years

-97.46%

5 Years

-99.45%

Alaunos Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

0.20%

EBIT Growth (5y)

14.23%

EBIT to Interest (avg)

-35.54

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.30

Sales to Capital Employed (avg)

0.02

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

11.31%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

2.60

EV to EBIT

-1.31

EV to EBITDA

-1.31

EV to Capital Employed

5.34

EV to Sales

5.34

PEG Ratio

Dividend Yield

ROCE (Latest)

-407.30%

ROE (Latest)

-142.49%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

Bearish

No Signal

Bollinger Bands

Mildly Bearish

Bullish

Moving Averages

Bearish (Daily)

KST

Bearish

Mildly Bearish

Dow Theory

No Trend

OBV

Mildly Bearish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 3 Schemes (2.41%)

Foreign Institutions

Held by 6 Foreign Institutions (0.08%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Sep 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 25.00% vs -9.09% in Sep 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.90",
          "val2": "-1.20",
          "chgp": "25.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-0.90",
          "val2": "-1.20",
          "chgp": "25.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-302,333.30%",
          "val2": "0.00%",
          "chgp": "-30,233.33%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 10.64% vs 86.61% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-4.20",
          "val2": "-4.80",
          "chgp": "12.50%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-4.20",
          "val2": "-4.70",
          "chgp": "10.64%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-845,000.00%",
          "val2": "-481,200.00%",
          "chgp": "-36,380.00%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ

Dec'25

Sep'25

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-0.90

-1.20

25.00%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-0.90

-1.20

25.00%

Operating Profit Margin (Excl OI)

-302,333.30%

0.00%

-30,233.33%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Sep 2025

Consolidated Net Profit

QoQ Growth in quarter ended Dec 2025 is 25.00% vs -9.09% in Sep 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-4.20

-4.80

12.50%

Interest

0.00

Exceptional Items

-0.00

0.00

Consolidate Net Profit

-4.20

-4.70

10.64%

Operating Profit Margin (Excl OI)

-845,000.00%

-481,200.00%

-36,380.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 10.64% vs 86.61% in Dec 2024

All Annual Results

Company CV

About Alaunos Therapeutics, Inc.

Alaunos Therapeutics, Inc.

Pharmaceuticals & Biotechnology

ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease. It has developed an adenoviral vector, Ad-RTS-IL-12, which is administered intra-tumorally under the control of the RheoSwitch Therapeutic System (RTS) expression platform. Its initial clinical stage product candidate, which is being developed using the immuno-oncology platform is Ad-RTS-IL-12 + veledimex. Ad-RTS-IL-12 + veledimex uses its gene delivery system to produce interleukin-12. As of December 31, 2016, it had completed two Phase II studies evaluating Ad-RTS-IL-12 + veledimex, for the treatment of metastatic melanoma and metastatic breast cancer.

Company Coordinates

Company Details

One First Avenue Parris Building 34 Navy Yard Plaza BOSTON MA : 02129

Tel: 1 617 25919701 617 5021881

http://www.ziopharm.com/

Registrar Details